<p>(A). Indicated cell lines were treated for 72 h with the AKT inhibitor MK2206, and effects on proliferation were determined by calculation of respective GI<sub>50</sub> values. (B/C). As in (A), except that indicated cell lines were treated for 62 h with either the PI3K inhibitor GDC0941 (B) or with the MEK inhibitor AZD6244 (C), and effects on proliferation were determined by calculation of respective GI<sub>50</sub> values. MCF7 cells were used as control for cells sensitive to GDC0941 and insensitive to AZD6244 and A375 cells were used as control for cells sensitive to AZD6244 and insensitive to GDC0941.</p
PURPOSE: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are ...
<p><i>A</i>, BT474 (left) and LNCaP (right) cell lines were treated with DMSO or GSK2110183 for 1 h....
<p>(A) Approximately two-day proliferation study performed with MOLM14-luc+ cells cultured in the pr...
<p>(A) Indicated cell lines (NT: non-targeting shRNA; 236 and 562: shRNAs targeting K-RAS) were eith...
<p>This model is based on our protein expression and phosphorylation measurements and viability assa...
<p>All four pancreatic cancer cell lines were treated with the GDC0941-AZD6244 combination for 24 ho...
Activating K-RAS mutations occur at a frequency of 90 % in pancreatic cancer, and to date no therapi...
<div><p>Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no ...
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapie...
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapie...
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapie...
<p>(a) Western blot results for pan-Akt, p-Akt (S473), p-Akt (T308), and tubulin in lysates from 42M...
<p>(A) Panc-1 cells were pre-incubated for 1 h with 20 µM, 10 µM and 1 µM of PD98059, an inhibitor o...
<p>(A–C) Approximately two-day proliferation studies performed with selective AKT inhibitors in comb...
PURPOSE:KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are p...
PURPOSE: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are ...
<p><i>A</i>, BT474 (left) and LNCaP (right) cell lines were treated with DMSO or GSK2110183 for 1 h....
<p>(A) Approximately two-day proliferation study performed with MOLM14-luc+ cells cultured in the pr...
<p>(A) Indicated cell lines (NT: non-targeting shRNA; 236 and 562: shRNAs targeting K-RAS) were eith...
<p>This model is based on our protein expression and phosphorylation measurements and viability assa...
<p>All four pancreatic cancer cell lines were treated with the GDC0941-AZD6244 combination for 24 ho...
Activating K-RAS mutations occur at a frequency of 90 % in pancreatic cancer, and to date no therapi...
<div><p>Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no ...
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapie...
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapie...
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapie...
<p>(a) Western blot results for pan-Akt, p-Akt (S473), p-Akt (T308), and tubulin in lysates from 42M...
<p>(A) Panc-1 cells were pre-incubated for 1 h with 20 µM, 10 µM and 1 µM of PD98059, an inhibitor o...
<p>(A–C) Approximately two-day proliferation studies performed with selective AKT inhibitors in comb...
PURPOSE:KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are p...
PURPOSE: KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are ...
<p><i>A</i>, BT474 (left) and LNCaP (right) cell lines were treated with DMSO or GSK2110183 for 1 h....
<p>(A) Approximately two-day proliferation study performed with MOLM14-luc+ cells cultured in the pr...